Clinical Effect of Hepatic Artery Chemoembolization Combined with CT Guided Percutaneous Puncture Implantation of 125I Particles in Advanced Liver Cancer
LEI Ting
ZHANG Xiaoyan
DONG Hao
Abstract：Objective To evaluate the clinical efficacy of transcatheter arterial chemoembolization(TACE)combined with CT guided percutaneous implantation of 125I particles in patients with advanced liver cancer.Methods A total of 84 patients with advanced liver cancer admitted to Xinyang Cancer Hospital from June 2020 to June 2023 were prospectively selected as the study subjects and randomly divided into control group and observation group,with 42 patients in each group.The control group received TACE treatment,while the observation group received TACE+CT guided percutaneous puncture implantation of 125I particles for treatment.Clinical efficacy,prognosis,liver cancer markers[alpha fetoprotein(AFP)]and liver function indicators[albumin(ALB),alanine aminotransferase(ALT),total bilirubin(TBIL)],immune function indicators(CD3+、CD4+、CD8+、CD4+/CD8+),as well as toxic side effects were compared between two groups.Results The objective remission rate,disease control rate,1-year survival rate,and average survival time of the observation group were higher,while the distant metastasis rate was lower(P＜0.05).After treatment,there was no statistical significant difference in the levels of ALB,ALT,and TBIL between the two groups(P＞0.05).But the serum AFP level in the observation group was lower(P＜0.05).After treatment,the levels of CD3+,CD4+,CD4+/CD8+in the observation group were higher,and CD8+was lower than those in the control group(P＜0.05).There was no statistical significant difference in the incidence of toxic side effects between the two groups(P＞0.05).Conclusion TACE combined with CT guided percutaneous implantation of 125I particles for the treatment of advanced liver cancer is effective,can prolong patient survival,reduce tumor marker levels,and has little impact on immune function,with good safety.
Keywords：transcatheter arterial chemoembolizationliver canceradvancedCT125I particle implantationsurvival periodimmune function
Publication Date：2025-11-13
Online Publishing Date：2026-09-12(First online date of this platform, not the publication date of the document)
Pages：4( 3917-3920 )